Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Risk stratification in heart failure decompensation in the community, HEFESTOS score

  • Verdú Rotellar, Jose María|||0000-0003-4225-8504
  • Abellana, Rosa|||0000-0003-4487-4431
  • Vaillant-Roussel, Helene
  • Gril Jevsek, Lea
  • Assenova, Radost
  • Lazic, Djurdjica Kasuba
  • Torsza, Peter
  • Glynn, Liam|||0000-0002-6153-9363
  • Lingner, Heidrun
  • Demurtas, Jacopo
  • Thulesius, Hans
  • Muñoz, Miguel-Angel|||0000-0002-4083-3248
Because evidence regarding risk stratification predicting prognosis of patients with heart failure (HF) decompensation attended in primary care is lacking, we developed and externally validated a model to forecast death/hospitalization during the first 30 days after an episode of decompensation. The predictive model is based on variables easily obtained in primary care settings. HEFESTOS is a multinational study consisting of a derivation cohort of HF patients recruited in 14 primary healthcare centres in Barcelona and a validation cohort from primary healthcare in 9 other European countries. The derivation and validation cohorts included 561 and 250 patients, respectively. Percentages of women in the derivation and validation cohorts were 56.3% and 47.6% (P = 0.026), respectively. Mean age was 82.2 years (SD 8.03) in the derivation cohort, and 79.3 years (SD 10.3) in the validation one (P = 0.001). HF with preserved ejection fraction represented 72.1% in the derivation cohort and 58.8% in the validation one (P = 0.004). Mortality/hospitalization during the first 30 days after a decompensation episode was 30.5% and 26% (P = 0.225) for the derivation and validation cohorts, respectively. Multivariable logistic regression models were performed to develop a score of risk. The identified predictors were worsening of dyspnoea [odds ratio (OR): 2.5; P = 0.001], orthopnoea (OR: 2.16; P = 0.01), paroxysmal nocturnal dyspnoea (OR: 2.25; P = 0.01), crackles (OR: 2.35; P = 0.01), New York Heart Association functional class III/IV (OR: 2.11; P = 0.001), oxygen saturation ≤ 90% (OR: 4.98; P.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Precipitating factors of heart failure decompensation, short-term morbidity and mortality in patients attended in primary care

  • Verdú Rotellar, Jose María|||0000-0003-4225-8504
  • Vaillant-Roussel, Helene
  • Abellana, Rosa|||0000-0003-4487-4431
  • Jevsek, Lea Gril
  • Assenova, Radost
  • Lazic, Djurdjica Kasuba
  • Torsza, Peter
  • Glynn, Liam|||0000-0002-6153-9363
  • Lingner, Heidrun
  • Demurtas, Jacopo
  • Borgström, Beata
  • Gibot-Boeuf, Sylvaine
  • Muñoz, Miguel-Angel|||0000-0002-4083-3248
To evaluate the precipitating factors for heart failure decompensation in primary care and associations with short-term prognosis. Design Prospective cohort study with a 30-d follow-up from an index consultation. Regression models to determine independent factors associated with hospitalisation or death. Primary care in ten European countries. Patients Patients with diagnosis of heart failure attended in primary care for a heart failure decompensation (increase of dyspnoea, unexplained weight gain or peripheral oedema). Potential precipitating factors for decompensation of heart failure and their association with the event of hospitalisation or mortality 30 d after a decompensation. Of 692 patients 54% were women, mean age 81 (standard deviation [SD] 8.9) years; mean left ventricular ejection fraction (LVEF) 55% (SD 12%). Most frequently identified heart failure precipitation factors were respiratory infections in 194 patients (28%), non-compliance of dietary recommendations in 184 (27%) and non-compliance with pharmacological treatment in 157 (23%). The two strongest precipitating factors to predict 30 d hospitalisation or death were respiratory infections (odds ratio [OR] 2.8, 95% confidence interval [CI] (2.4-3.4)) and atrial fibrillation (AF).